| Literature DB >> 35309860 |
Bridget Sinnott1, Cara Ray2, Frances Weaver2,3, Beverly Gonzalez2,4,5,6, Elizabeth Chu7, Sarah Premji7, Mattie Raiford7, Rachel Elam1,7, Scott Miskevics2, Stephen Parada8, Laura Carbone1,7.
Abstract
We used Veterans Health Administration (VHA) national administrative data files to identify a cohort (fiscal years 2005-2014) of veterans with spinal cord injuries and disorders (SCID) to determine risk factors for and consequences of lower extremity fracture nonunions. Odds ratios (OR) for fracture nonunion were computed using multivariable-adjusted logistic regression models. We identified three risk factors for nonunion: (i) older age (OR = 2.29; 95% confidence interval [CI] 1.21-4.33), (ii) longer duration of SCID (OR = 1.02; 95% CI 1.00-1.04), and (iii) fracture site (distal femur), with OR (comparison distal femur) including distal tibia/fibula (OR = 0.14; 95% CI 0.09-0.24), proximal tibia/fibula (OR = 0.19; 95% CI 0.09-0.38), proximal femur (OR = 0.10; 95% CI 0.04-0.21), and hip (OR = 0.13; 95% CI 0.07-0.26). Nonunions resulted in multiple complications, with upwards of 1/3 developing a pressure injury, 13% osteomyelitis, and almost 25% requiring a subsequent amputation. Our data have identified a high-risk population for fracture nonunion of older veterans with a long duration of SCID who sustain a distal femur fracture. In view of the serious complications of these nonunions, targeted interventions in these high-risk individuals who have any signs of delayed union should be considered.Entities:
Keywords: FEMUR FRACTURES; FRACTURE NONUNION; FRACTURE‐RELATED COMPLICATIONS; SPINAL CORD INJURY AND DISORDERS
Year: 2022 PMID: 35309860 PMCID: PMC8914149 DOI: 10.1002/jbm4.10595
Source DB: PubMed Journal: JBMR Plus ISSN: 2473-4039
Fig. 1(A) Flow diagram of study cases. (B) Flow diagram of study controls.
Baseline Characteristics of Subset of Study Population with Fracture Nonunion
| Patient characteristics | Patients without fracture nonunion ( | Patients with fracture nonunion ( |
|
|---|---|---|---|
| Clinical characteristics | |||
| Age (years), mean ± SD | 57.45 ± 12.67 | 61.91 ± 12.01 |
|
| Race, | 0.7436 | ||
| White | 1228 (70.33) | 75 (70.75) | |
| Black | 327 (18.73) | 17 (16.04) | |
| Other | 42 (2.41) | 4 (3.77) | |
| Missing | 149 (8.53) | 10 (9.43) | |
| Sex, | 0.2768 | ||
| Male | 1670 (95.65) | 99 (93.4) | |
| Female | 34 (4.35) | 7 (6.6) | |
| Body mass index, | 0.1738 | ||
| Underweight | 109 (6.24) | 2 (1.89) | |
| Normal | 634 (36.31) | 38 (35.85) | |
| Overweight | 587 (33.62) | 35 (33.02) | |
| Obese | 247 (21.59) | 31 (29.25) | |
| Missing | 21 (1.2) | 0 (0) | |
| Comorbidities, | 0.3651 | ||
| Diabetes mellitus | 426 (24.40) | 30 (28.3) | 0.9516 |
| Chronic kidney disease | 129 (7.39) | 8 (7.55) | 0.3574 |
| Peripheral vascular disease | 196 (11.23) | 15 (14.15) | |
| Medication use, | |||
| Bisphosphonates | 152 (8.71) | 16 (15.09) |
|
| Anticonvulsants | 777 (44.5) | 51 (48.11) | 0.4678 |
| Benzodiazepines | 848 (48.57) | 56 (52.83) | 0.3940 |
| Opioids | 1196 (68.5) | 73 (68.87) | 0.9368 |
| Corticosteroids | 230 (13.17) | 14 (13.21) | 0.9918 |
| Antidepressants | 940 (53.84) | 58 (54.72) | 0.8600 |
| Anticoagulants | 273 (15.64) | 24 (22.64) | 0.0563 |
| SCI‐related characteristics | |||
| Etiology of injury, | 0.0546 | ||
| Traumatic | 1239 (70.96) | 75 (70.75) | |
| Non‐traumatic | 470 (26.92) | 25 (25.58) | |
| Missing | 37 (2.12) | 6 (5.66) | |
| Level of injury, | 0.1708 | ||
| Paraplegia | 911 (52.18) | 62 (60.78) | |
| Tetraplegia | 799 (45.76) | 40 (39.22) | |
| Missing | 36 (2.06) | 4 (3.77) | |
| Extent of injury, | 0.1909 | ||
| Complete | 818 (46.85) | 58 (54.72) | |
| Incomplete | 696 (39.86) | 39 (36.79) | |
| Missing | 232 (13.29) | 9 (8.49) | |
| ASIA impairment scale | 0.0608 | ||
| A | 509 (29.15) | 41 (38.68) | |
| B | 122 (6.99) | 8 (7.55) | |
| C | 116 (6.64) | 11 (10.38) | |
| D | 200 (11.45) | 7 (6.6) | |
| Missing | 799 (45.76) | 39 (36.79) | |
| Duration of SCID, mean ± SD | 19.71 ± 14.55 | 23.46 ± 15.60 |
|
| Fracture‐related characteristics | |||
| Primary fracture treatment, | |||
| Surgical | 168 (9.62) | 14 (13.21) | 0.2286 |
| Non‐surgical | 1578 (90.38) | 92 (86.79) | |
| Fracture site, |
| ||
| Distal tibia/fibula | 769 (44.04) | 28 (26.42) | |
| Proximal tibia/fibula | 187 (10.71) | 9 (8.49) | |
| Distal femur | 171 (9.79) | 49 (46.23) | |
| Proximal femur | 275 (15.75) | 7 (6.60) | |
| Hip | 260 (22.73) | 13 (12.26) | |
| Fracture type; unknown type categorized as closed, | 0.4640 | ||
| Closed | 1714 (98.17) | 103 (97.17) | |
| Open | 32 (1.83) | 3 (2.83) | |
| Fracture type; unknown type categorized as open, |
| ||
| Closed | 1714 (98.17) | 96 (90.57) | |
| Open | 32 (1.83) | 10 (9.43) | |
ASIA = American Spinal Injury Association Impairment Scale; SCID = spinal cord injuries and disorders.
Bolded p values indicate the result was significant at the 0.05 level.
Two‐sample t test.
Pearson's chi‐square.
Predictors of Fracture Nonunion in Those With Lower Extremity Fractures
| Predictors | Univariate | Multivariate |
|---|---|---|
| OR (95% CI) | OR (95% CI) | |
| Clinical characteristics | ||
| Age (≥50 versus <50 years) |
|
|
| Race | ||
| Black versus white | 0.87 (0.51–1.48) | 0.95 (0.54–1.67) |
| Other versus white | 1.72 (0.63–4.73) | 1.63 (0.55–4.84) |
| Sex (female versus male) | 1.65 (0.75–3.59) | 1.99 (0.82–4.88) |
| BMI (normal versus underweight) | 2.66 (0.72–9.75) | 2.51 (0.69–9.10) |
| BMI (overweight versus underweight) | 2.65 (0.72–9.74) | 2.58 (0.71–9.44) |
| BMI (obese versus underweight) | 3.49 (0.94–12.93) | 3.68 (0.99–13.74) |
| Diabetes mellitus (yes versus no) | 1.23 (0.80–1.91) | 0.90 (0.55–1.48) |
| Chronic kidney disease (yes versus no) | 1.08 (0.52–2.23) | 1.00 (0.46–2.17) |
| Peripheral vascular disease (yes versus no) | 1.34 (0.76–2.34) | 1.02 (0.56–1.86) |
| Anticonvulsants (yes versus no) | 1.16 (0.78–1.71) | 1.09 (0.69–1.73) |
| Benzodiazepines (yes versus no) | 1.19 (0.80–1.75) | 1.05 (0.68–1.62) |
| Opioids (yes versus no) | 1.01 (0.66–1.54) | 1.05 (0.64–1.71) |
| Antidepressants (yes versus no) | 1.03 (0.70–1.53) | 0.84 (0.53–1.34) |
| Anticoagulants (yes versus no) |
| 1.46 (0.88–2.42) |
| Corticosteroids (yes versus no) | 1.03 (0.58–1.83) | 0.95 (0.52–1.74) |
| Bisphosphonates (yes versus no) |
| 1.46 (0.80–2.66) |
| SCID‐related characteristics | ||
| Etiology (nontraumatic versus traumatic) | 0.89 (0.56–1.41) | 1.00 (0.59–1.70) |
| SCI level (tetraplegia versus paraplegia) | 0.74 (0.49–1.11) | 0.91 (0.59–1.40) |
| SCI extent (incomplete versus complete) | 0.79 (0.52–1.20) | 1.05 (0.51–2.15) |
| ASIA Impairment Scale | ||
| B versus A | 0.85 (0.40–1.83) | 1.23 (0.44–3.45) |
| C versus A | 1.21 (0.61–2.41) | 1.50 (0.55–4.06) |
| D versus A | 0.46 (0.21–1.02) | 0.74 (0.26–2.10) |
| Missing versus A | 0.61 (0.39–0.95) | 0.75 (0.42–1.33) |
| Duration of SCID |
|
|
| Fracture‐related characteristics | ||
| Primary fracture treatment (operative versus nonoperative) | 1.47 (0.82–2.62) |
|
| Fracture site | ||
| Distal tibia/fibula versus distal femur |
|
|
| Proximal tibia/fibula versus distal femur |
|
|
| Proximal femur versus distal femur |
|
|
| Hip versus distal femur |
|
|
| Type of fracture (open versus closed) | 1.78 (0.57–5.55) | 2.23 (0.67–7.43) |
Note: Bolded odds ratio estimates and confidence intervals indicate the result was significant at the 0.05 level.
BMI = body mass index; SCID = spinal cord injuries and disorders; ASIA = American Spinal Injury Association Impairment Scale.
In the analyses detailed in this table, the 7 fractures that had unknown type (open versus closed), all of which came from those fractures resulting in nonunion, were assumed to be closed fractures.
Complications of Lower Extremity Fracture Nonunions
| Complications ( | Fracture nonunion |
|---|---|
| ( | |
| Pressure injury | 36 (33.96%) |
| Osteomyelitis | 14 (13.21%) |
| Amputation | 25 (23.58%) |
| Thrombosis | 1 (0.94%) |
| Other | 5 (4.72%) |
Septic arthritis, localized osteopenia, myositis ossificans.
Treatments for Lower Extremity Fracture Nonunions
| Fracture nonunion treatment ( | Fracture nonunion |
|---|---|
| ( | |
| Surgery | |
| New hardware | 21 (19.81%) |
| Revision | 8 (7.55%) |
| Bone graft | |
| Autografts | 4 (3.77%) |
| Allografts | 1 (0.94%) |
| Bone stimulator | |
| Orthofix or pulsed electromagnetic fields | 11 (10.38%) |
| Exon ultrasonography | 6 (5.66%) |
| Other | 0 |
| Biologics | |
| Bone morphogenetic protein (BMP) | 1 (0.94%) |
| Fibroblast growth factor 2 (FGF‐2) | 0 |
| Platelet‐derived growth factor (PDGF) | 0 |
| Medications | |
| Teriparatide | 0 |
| Abaloparatide | 0 |